Recursion Pharmaceuticals just hit a 52-week low. Is this former Nvidia holding a smart buy ...

The stock looks cheap, but appearances can be deceiving.
Nasdaq

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...

Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs.
Forbes

Recursion Announces New Generative AI Platform To Speed Up Drug Discovery

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...